ANTHEM Anthem Biosciences Q1 FY26 results (Apr–Jun 2025) and concall
Anthem Biosciences reported a strong Q1 FY26 with consolidated revenue of INR 540 crores and an EBITDA margin of 38%, driven by ramping CRDM business and increased demand for commercial products. The company added 54 kiloliters of custom synthesis capacity and moved two Phase 3 products to commercial. Management cautioned about the lumpiness of the business and the exceptional nature of the quarter, while maintaining a positive outlook for GLP-1 and new modalities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 525 | 498 | 479 | 538 |
| EBITDA | 201 | 167 | 198 | 195 |
| Net profit | 170 | 128 | 123 | 148 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
